Evidence map›Paper›PMID 39224814›Full record

ArticleFrontiers in oncology2024

Prevalence of alternative lengthening of telomeres in pediatric sarcomas determined by the telomeric DNA C-circle assay.

Trevor A Burrow, Balakrishna Koneru, Shawn J Macha, Wenyue Sun, Frederic G Barr, Timothy J Triche, C Patrick Reynolds

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Trevor A BurrowDepartment of Pediatrics, Texas Tech University Health Sciences Center School of Medicine Cancer Center, Lubbock, TX, United States.
Balakrishna KoneruDepartment of Pediatrics, Texas Tech University Health Sciences Center School of Medicine Cancer Center, Lubbock, TX, United States.
Shawn J MachaDepartment of Pediatrics, Texas Tech University Health Sciences Center School of Medicine Cancer Center, Lubbock, TX, United States.
Wenyue SunLaboratory of Pathology, National Cancer Institute, Bethesda, MD, United States.
Frederic G BarrLaboratory of Pathology, National Cancer Institute, Bethesda, MD, United States.
Timothy J TricheChildren's Hospital Los Angles, Department of Pathology and Laboratory Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA, United States.
C Patrick ReynoldsDepartment of Pediatrics, Texas Tech University Health Sciences Center School of Medicine Cancer Center, Lubbock, TX, United States.

Funding

Targeting Shared Vulnerabilities in Alternate Telomere Lengthening (ALT) CancersR01CA264949 · NCI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI CHARLES Patrick REYNOLDS · 2022 to 2026
$1.9M
Robust assays to define telomere maintenance mechanisms as cancer biomarkers.U01CA263988 · NCI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI REYNOLDS, CHARLES PATRICK · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA264949NCI NIH HHS U01 CA263988
6 · The paper itself

Abstract

Introduction: Alternative lengthening of telomeres (ALT) occurs in sarcomas and ALT cancers share common mechanisms of therapy resistance or sensitivity. Telomeric DNA C-circles are self-primed circular telomeric repeats detected with a PCR assay that provide a sensitive and specific biomarker exclusive to ALT cancers. We have previously shown that 23% of high-risk neuroblastomas are of the ALT phenotype. Here, we investigate the frequency of ALT in Ewing's family sarcoma (EFS), rhabdomyosarcoma (RMS), and osteosarcoma (OS) by analyzing DNA from fresh frozen primary tumor samples utilizing the real-time PCR C-circle Assay (CCA). Methods: We reviewed prior publications on ALT detection in pediatric sarcomas. DNA was extracted from fresh frozen primary tumors, fluorometrically quantified, C-circles were selectively enriched by isothermal rolling cycle amplification and detected by real-time PCR. Results: The sample cohort consisted of DNA from 95 EFS, 191 RMS, and 87 OS primary tumors. One EFS and 4 RMS samples were inevaluable. Using C-circle positive (CC+) cutoffs previously defined for high-risk neuroblastoma, we observed 0 of 94 EFS, 5 of 187 RMS, and 62 of 87 OS CC+ tumors. Conclusions: Utilizing the ALT-specific CCA we observed ALT in 0% of EFS, 2.7% of RMS, and 71% of OS. These data are comparable to prior studies in EFS and OS using less specific ALT markers. The CCA can provide a robust and sensitive means of identifying ALT in sarcomas and has potential as a companion diagnostic for ALT targeted therapeutics.

Indexed as

alternative lengthening of telomeresEwing sarcomaosteosarcomarhabdomyosarcomatelomere

Identifiers

PMID39224814
PMCPMC11366626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.